home / stock / vtyx / vtyx message board
Subject | By | Source | When |
---|---|---|---|
just the news we needed | DewDiligence | investorshub | 07/02/2023 2:16:23 AM |
Price now up | crudeoil24 | investorshub | 06/13/2023 7:26:13 PM |
just the news we needed | crudeoil24 | investorshub | 06/12/2023 8:45:23 AM |
Ventyx Biosciences, Inc. (Nasdaq: $VTYX) (Ventyx), a clinical-stage | crudeoil24 | investorshub | 09/19/2022 4:15:16 PM |
znewcar1: VTYX 64% v15,6M c38.11 f50,9M H41.29 ML16.91 off the 20dma@19.73 | znewcar1 | investorshangout | 09/13/2022 1:57:39 AM |
$VTYX IS A GREAT $$$$$ OPPORTUNITY. | crudeoil24 | investorshub | 09/12/2022 6:37:24 PM |
Complex, but GOOD!!! | Invest-in-America | investorshub | 09/12/2022 6:21:00 PM |
Ventyx Shares Surge 59% After Bristol Myers Drug | crudeoil24 | investorshub | 09/12/2022 6:19:20 PM |
THANKS!! | Invest-in-America | investorshub | 09/12/2022 6:06:18 PM |
Today's pop is due to $BMY's FDA approval | DewDiligence | investorshub | 09/12/2022 6:04:12 PM |
$VTYX: Soaring today??? | Invest-in-America | investorshub | 09/12/2022 2:39:50 PM |
znewcar1: VTYX 31% v2,1M c24.55 f50,8M H27.65 ML12.87 | znewcar1 | investorshangout | 08/16/2022 8:32:06 PM |
VTYX reports phase-1 data for VTX858, a potential | DewDiligence | investorshub | 08/15/2022 9:41:23 PM |
$VTYX: $125Mlly IPO coming........... | makinezmoney | investorshub | 10/18/2021 6:44:14 PM |
News, Short Squeeze, Breakout and More Instantly...
Ventyx Biosciences Inc. Company Name:
VTYX Stock Symbol:
NASDAQ Market:
Ventyx Biosciences Inc. Website:
A look at the top 10 most actives in the United States Freight Technologies Inc. (FRGT) rose 10.4% to $0.6899 on volume of 220,478,071 shares Nauticus Robotics Inc. (KITT) rose 23.2% to $0.17 on volume of 217,326,595 shares GameStop Corporation (GME) rose 47.5% to $46.55 on volume of 178,...
VTX3232 demonstrated improvements in body weight, systemic inflammatory biomarkers and cardiometabolic parameters in diet-induced obesity (DIO) mice Additive effects were observed for VTX3232 in combination with the GLP-1 receptor agonist semaglutide across key endpoints compared to semag...
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced th...